Annovis Bio IncNYSE ANVS Stock Report

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania and currently employs 3 full-time employees. The company went IPO on 2020-01-29. The firm is engaged in developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (AD-DS). The firm's lead compound, Buntanetap, is an orally administered drug being developed for chronic indications such as AD, PD and AD-DS. The firm's ANVS405 compound is being developed for acute indications, focused on protecting the brain after Traumatic brain injury (TBI) and/or stroke. Its ANVS405 is the same compound as Buntanetap, but it is given intravenously in cases of acute head and brain trauma. The firm is also developing its compound, ANVS301 to increase cognitive capability in later stages of AD and dementia.